Intravenous Pegloticase Market Outlook:
Intravenous Pegloticase Market size was over USD 4.14 billion in 2025 and is anticipated to cross USD 15.62 billion by 2035, witnessing more than 14.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of intravenous pegloticase is assessed at USD 4.67 billion.
The market is growing as a result of the rising prevalence of chronic and refractory gout among the global population. Intravenous pegloticase is used for the treatment of chronic and refractory gout in adults. It lowers uric acid levels and is typically prescribed when standard treatment has been ineffective. According to research, roughly 9.2 million people are afflicted with chronic and refractory gout, with men diagnosed more often than women.
In addition to these, the intravenous pegloticase market growth is owing to the aging global population. Gout typically occurs in men who are between the ages of forty and fifty years old. With people living longer lives than average, there is an increase in the number of geriatric people worldwide.